Reuters logo
BRIEF-AGTC files investigational new drug application for treatment of x-linked retinitis pigmentosa
August 10, 2017 / 11:30 AM / 4 months ago

BRIEF-AGTC files investigational new drug application for treatment of x-linked retinitis pigmentosa

Aug 10 (Reuters) - Applied Genetic Technologies Corp

* AGTC files investigational new drug application for the treatment of x-linked retinitis pigmentosa caused by mutations in the RPGR gene

* Applied Genetic Technologies-to initiate study evaluating safety & efficacy of gene therapy for XLRP caused by RPGR gene mutations in U.S. in coming months​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below